4.7 Article

Stimuli-responsive hybrid nanocarriers developed by controllable integration of hyperbranched PEI with mesoporous silica nanoparticles for sustained intracellular siRNA delivery

期刊

INTERNATIONAL JOURNAL OF NANOMEDICINE
卷 11, 期 -, 页码 6591-6608

出版社

DOVE MEDICAL PRESS LTD
DOI: 10.2147/IJN.S120611

关键词

mesoporous silica nanoparticles; RNAi therapy; siRNA delivery; stimuli-responsive drug release; hybrid nanocarriers

资金

  1. Jane and Aatos Erkko Foundation
  2. Sigrid Juselius Foundation
  3. Foundation for Finnish Cancer Institute
  4. Academy of Finland [260599, 284542]
  5. Suomen Kulttuurirahasto
  6. Forskarskolan vid Abo Akademi
  7. National Natural Science Foundation of China (NSFC) [51502027]
  8. Basic Advanced Research Project of Chongqing 572 [cstc2015jcyjA10051]
  9. Doctoral Education Network in Materials Research at Abo Akademi University
  10. Agency for Management of University and Research Grants from Generalitat de Catalunya (AGAUR) through Beatriu de Pinos program [2014 BP_A 00132]

向作者/读者索取更多资源

Small interfering RNA (siRNA) is a highly potent drug in gene-based therapy with the challenge being to deliver it in a sustained manner. The combination of mesoporous silica nanoparticles (MSNs) and polycations in the confined pore space allows for incorporation and controlled release of therapeutic siRNA payloads. We hereby constructed MSNs with expanded mesopores and pore-surface-hyperbranched poly(ethyleneimine) (PEI) tethered with redox-cleavable linkers that could carry a high payload of siRNA (120 mg center dot g(-1)). The developed nanocarriers were efficiently taken up by cancer cells and were subsequently able to escape to the cytoplasm from the endosomes, most likely owing to the integrated PEI. Triggered by the intracellular redox conditions, the siRNA was sustainably released inside the cells over a period of several days. Functionality of siRNAs was demonstrated by using cell-killing siRNA as cargo. Despite not being the aim of the developed system, in vitro experiments using cell-killing siRNAs showed that the efficacy of siRNA transfection was comparable to the commercial in vitro transfection agent Lipofectamine. Consequently, the developed MSN-based delivery system offers a potential approach to hybrid nanocarriers for more efficient and long-term siRNA delivery and, in a longer perspective, in vivo gene silencing for RNA interference (RNAi) therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据